Lipid safety of tenofovir alafenamide during 96-week treatment in treatment-naive chronic hepatitis B patients.

Front Med (Lausanne) · 2024 · PMC11183333 · PMID 38895186

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Patients with CHB combined with hypercholesterolemia showed a trend towards lower TC and LDL-C levels with TAF for 96W, but there was no significant difference, and no significant change in TG levels.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.